Published in Nature on September 09, 1999
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A (2000) 5.53
The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol (2002) 5.37
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev (2007) 4.50
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science (2009) 4.45
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J (2003) 3.96
Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem (2009) 3.88
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A (2004) 3.86
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A (2007) 3.60
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Chemical probes for histone-modifying enzymes. Nat Chem Biol (2008) 3.30
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A (2004) 3.27
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol (2004) 3.00
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A (2002) 2.91
Coupling of histone deacetylation to NAD breakdown by the yeast silencing protein Sir2: Evidence for acetyl transfer from substrate to an NAD breakdown product. Proc Natl Acad Sci U S A (2000) 2.61
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene (2009) 2.49
A fully automatic evolutionary classification of protein folds: Dali Domain Dictionary version 3. Nucleic Acids Res (2001) 2.32
An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J Am Chem Soc (2010) 2.30
Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A (2001) 2.23
Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med (2011) 2.17
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem (2008) 2.12
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med (2006) 2.11
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem (2008) 2.09
Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci U S A (2007) 2.03
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep (2007) 2.01
Identification of Arabidopsis histone deacetylase HDA6 mutants that affect transgene expression. Plant Cell (2001) 1.87
Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. Mol Cell Biol (2002) 1.84
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
Experience-dependent epigenetic modifications in the central nervous system. Biol Psychiatry (2008) 1.79
The role of HDAC6 in cancer. J Biomed Biotechnol (2010) 1.77
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci (2014) 1.74
Isoform-selective histone deacetylase inhibitors. Chem Soc Rev (2008) 1.72
Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. Proc Natl Acad Sci U S A (2000) 1.71
Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem (2008) 1.68
Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry (2008) 1.68
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
Identification of a nuclear domain with deacetylase activity. Proc Natl Acad Sci U S A (2000) 1.64
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics (2012) 1.61
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res (2008) 1.60
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol (2004) 1.60
Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res (2010) 1.53
Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) (2011) 1.52
Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc Natl Acad Sci U S A (2003) 1.52
Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging. FASEB J (2005) 1.52
Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther (2010) 1.51
Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One (2007) 1.50
Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics (2012) 1.49
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis (2005) 1.46
Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors. Mol Cell Biol (2008) 1.46
Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther (2010) 1.45
Structural Basis for Ceramide Recognition and Hydrolysis by Human Neutral Ceramidase. Structure (2015) 1.45
Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J (2000) 1.42
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. J Med Chem (2009) 1.42
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab (2008) 1.40
Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J Biol Chem (2005) 1.39
Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci U S A (2001) 1.39
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene (2011) 1.38
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr Opin Struct Biol (2011) 1.35
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35
Mechanisms of HDA6-mediated rRNA gene silencing: suppression of intergenic Pol II transcription and differential effects on maintenance versus siRNA-directed cytosine methylation. Genes Dev (2010) 1.34
SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat Neurosci (2013) 1.30
Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob Agents Chemother (2008) 1.26
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24
Sleeping beauty transposase has an affinity for heterochromatin conformation. Mol Cell Biol (2006) 1.23
Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J Cell Biol (2002) 1.23
Small-molecule microarrays as tools in ligand discovery. Chem Soc Rev (2008) 1.23
Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc Natl Acad Sci U S A (2002) 1.22
Chromatin, cancer and drug therapies. Mutat Res (2008) 1.21
Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol (2014) 1.18
Activation and inhibition of histone deacetylase 8 by monovalent cations. J Biol Chem (2009) 1.18
On the inhibition of histone deacetylase 8. Bioorg Med Chem (2010) 1.18
The NuRD architecture. Cell Mol Life Sci (2013) 1.18
A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med (2012) 1.18
A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions. J Am Chem Soc (2010) 1.14
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegener (2013) 1.12
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis (2011) 1.12
Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen (2009) 1.11
Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem (2009) 1.11
Functional requirement for histone deacetylase 1 in Caenorhabditis elegans gonadogenesis. Mol Cell Biol (2002) 1.11
Histone deacetylase inhibitors through click chemistry. J Med Chem (2008) 1.10
Evolution of the arginase fold and functional diversity. Cell Mol Life Sci (2008) 1.09
Histone deacetylases play distinct roles in telomeric VSG expression site silencing in African trypanosomes. Mol Microbiol (2010) 1.09
A Class 1 Histone Deacetylase with Potential as an Antifungal Target. MBio (2016) 1.09
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chem Biol (2010) 1.09
HDAC8 substrates: Histones and beyond. Biopolymers (2013) 1.08
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J Exp Med (2009) 1.08
Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology (2009) 1.07
Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol Learn Mem (2011) 1.07
Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics (2011) 1.07
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer (2010) 1.07
Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells. J Med Chem (2008) 1.07
Trans-regulation of histone deacetylase activities through acetylation. J Biol Chem (2009) 1.06
Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science (1996) 19.48
MINIATURE escherichia coli CELLS DEFICIENT IN DNA. Proc Natl Acad Sci U S A (1967) 19.02
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet (2001) 11.12
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Exposure measurement error in time-series studies of air pollution: concepts and consequences. Environ Health Perspect (2000) 9.30
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 9.03
Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell (2000) 7.82
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (1996) 6.67
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell (1999) 6.59
Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med (1994) 6.05
Effects of colchicine and related substances on cell division. Biochem J (1936) 5.80
Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res (2001) 5.78
Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 5.73
Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science (1999) 5.72
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A (2000) 5.53
Absorption of guinea pig serum with agar. A method for elimination of itscytotoxicity for murine thymus cells. Transplantation (1970) 5.37
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
Erythroleukemic differentiation. Annu Rev Biochem (1978) 5.19
Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature (2000) 4.52
Mouse actin messenger RNAs. Construction and characterization of a recombinant plasmid molecule containing a complementary DNA transcript of mouse alpha-actin mRNA. J Biol Chem (1981) 4.30
Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science (1999) 4.21
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell (1998) 3.86
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A (2004) 3.86
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol (1996) 3.81
Three cdg operons control cellular turnover of cyclic di-GMP in Acetobacter xylinum: genetic organization and occurrence of conserved domains in isoenzymes. J Bacteriol (1998) 3.81
A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci U S A (1976) 3.70
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (1995) 3.69
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A (1998) 3.62
In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol (1998) 3.38
A clinical trial of active management of labor. N Engl J Med (1995) 3.34
A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature (1997) 3.29
In vitro synthesis of DNA components of human genes for globins. Nat New Biol (1972) 3.23
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature (1998) 3.01
Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol (2001) 2.91
The properties of DNA transferred to minicells during conjugation. Cold Spring Harb Symp Quant Biol (1968) 2.86
Primary cardiac valve tumors. Ann Thorac Surg (1991) 2.85
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A (1978) 2.78
Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev (1999) 2.73
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A (1996) 2.72
Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell (1994) 2.69
Expression and biologic characterization of the murine chemokine KC. J Immunol (1995) 2.66
Synthesis of linear plasmid multimers in Escherichia coli K-12. J Bacteriol (1986) 2.65
Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun (1988) 2.65
Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proc Natl Acad Sci U S A (1975) 2.60
Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A (2001) 2.55
Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med (1996) 2.55
Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature (1998) 2.52
Increased efficiency of exogenous messenger RNA translation in a Krebs ascites cell lysate. Proc Natl Acad Sci U S A (1972) 2.49
Erythropoietic differentiation in colonies of cells transformed by Friend virus. Proc Natl Acad Sci U S A (1974) 2.47
Structure of the histone deacetylase SIRT2. Nat Struct Biol (2001) 2.37
Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells. Cancer Res (1977) 2.26
The relationship between gastroesophageal reflux and apnea in infants. J Pediatr (2000) 2.24
A single locus in the mouse encodes both myosin light chains 1 and 3, a second locus corresponds to a related pseudogene. Cell (1984) 2.19
Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci U S A (2001) 2.19
Postcholecystectomy biliary leaks in the laparoscopic era: risk factors, presentation, and management. McGill Gallstone Treatment Group. Gastrointest Endosc (1997) 2.15
Successful treatment of primary amebic meningoencephalitis. N Engl J Med (1982) 2.14
Induction of erythroid differentiation by dimethylsulfoxide in cells infected with Friend virus: relationship to the cell cycle. Proc Natl Acad Sci U S A (1975) 2.12
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A (2008) 2.10
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
Tumor promoters inhibit spontaneous and induced differentiation of murine erythroleukemia cells in culture. Proc Natl Acad Sci U S A (1977) 2.09
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res (2001) 2.08
Decreased globin messenger RNA in thalassemia detected by molecular hybridization. Proc Natl Acad Sci U S A (1973) 2.07
Percutaneous dilational tracheostomy. A bedside procedure on the intensive care unit. Anaesthesia (1991) 2.07
Polyribosome dissociation and formation in intact reticulocytes with conservation of messenger ribonucleic acid. Proc Natl Acad Sci U S A (1965) 2.06
Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol (2009) 2.06